These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 7009256)

  • 1. Once daily beta-blocker in hypertension--oxprenolol slow-release.
    Gordon RD; Ziesak M; Rowe WS; Strakosch CR; Row G
    J Int Med Res; 1981; 9(1):6-11. PubMed ID: 7009256
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Experience with a slow-release formulation of oxprenolol.
    Waal-Manning HJ; Spears GF
    N Z Med J; 1978 Apr; 87(609):245-6. PubMed ID: 275650
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of a slow release formulation of oxprenolol with conventional oxprenolol in the treatment of hypertension.
    O'Brien KP; Stephens EJ
    N Z Med J; 1976 Aug; 84(570):142-4. PubMed ID: 1069924
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Once daily administration of a beta-blocker in hypertension.
    Watt M; Duncan TD
    N Z Med J; 1978 Feb; 87(606):126-8. PubMed ID: 274648
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oxprenolol slow-release with cyclopenthiazide KCl in the treatment of essential hypertension. A multicentre general practice study.
    Levenstein JH
    S Afr Med J; 1981 Jun; 59(25):893-9. PubMed ID: 7015537
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Exercise and resting blood pressure and heart rate changes 24 h after dosing in patients with essential hypertension receiving 16/260 oxprenolol Oros once daily.
    Müller FB; Allsopp LF; Cooper GL; Bolli P; Frei P; Glaus L; Ritz R; Bühler FR
    Br J Clin Pharmacol; 1985; 19 Suppl 2(Suppl 2):207S-212S. PubMed ID: 4005124
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oxprenolol slow-release with cyclopenthiazide-KCl compared with methyldopa in the treatment of essential hypertension. A multicentre general practice trial.
    Levenstein JH
    S Afr Med J; 1978 Nov; 54(21):860-4. PubMed ID: 371021
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A fixed combination of oxprenolol slow-release and chlorthalidone once daily in treatment of mild to moderate hypertension.
    Muiesan G; Agabiti-Rosei E; Buoninconti R; Carotti A; Fariello R; Innocenti P; Toso M; Valori C; Motolese M
    Int J Clin Pharmacol Ther Toxicol; 1981 Jun; 19(6):249-55. PubMed ID: 7309298
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A comparison of slow release oxprenolol with conventional oxprenolol in the treatment of hypertension.
    Resnekov EB; Havard CW
    Eur J Clin Pharmacol; 1978 Nov; 14(2):77-81. PubMed ID: 363434
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of a sustained-release formulation of oxprenolol and cyclopenthiazide ('Trasidrex') in the management of hypertension: a general practice study.
    Forrest WA
    Curr Med Res Opin; 1980; 6(8):559-63. PubMed ID: 7389387
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Slow-release oxprenolol compared with oxprenolol in hypertensive patients: a multicenter clinical trial.
    Materson BJ; Friedman BA; Hla KM; Neidorf BS; Gray JM; Glazer N; Gross S
    Drug Intell Clin Pharm; 1983 Jan; 17(1):51-4. PubMed ID: 6337801
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of a slow-release formulation of oxprenolol with conventional oxprenolol in the treatment of hypertension.
    O'Brien KP; Stephens EJ
    Clin Sci Mol Med Suppl; 1976 Dec; 3():559s-561s. PubMed ID: 1071681
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and tolerability of long term oxprenolol and chlorthalidone singly and in combination in hypertensive blacks.
    Obel AO
    Jpn Heart J; 1990 Mar; 31(2):183-92. PubMed ID: 2192098
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of atenolol and oxprenolol in the treatment of arterial hypertension. A comparison.
    Turner AS; Watson OF; Brocklehurst JE
    Med J Aust; 1979 Jun; 1(13):625-6. PubMed ID: 386061
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A multicentre evaluation of sustained release oxprenolol in the management of hypertension in hospital out-patient practice.
    Forrest WA
    J Int Med Res; 1978; 6(2):136-40. PubMed ID: 631415
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A comparison of slow Trasicor (oxprenolol 160 mg) and Trasidrex (oxprenolol 160 mg and cyclopenthiazide 0.25 mg) in the treatment of hypertension in general practice.
    Elsdon-Dew RW; Holden E
    J Int Med Res; 1981; 9(5):315-8. PubMed ID: 7028531
    [No Abstract]   [Full Text] [Related]  

  • 17. Antihypertensive effectiveness of oxprenolol administered twice daily.
    Materson BJ; Oster JR; Michael UF; Perez-Stable EC
    Clin Pharmacol Ther; 1976 Mar; 19(3):325-32. PubMed ID: 770050
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A double-blind study of oxprenolol once and twice daily in hypertensive patients.
    Glazer N; Friedman B; Gerlings E; Gross S; Lowney C; Solomon R
    Clin Cardiol; 1983 Aug; 6(8):378-83. PubMed ID: 6352119
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antihypertensive effect of oxprenolol and chlorthalidone in fixed combination, given once daily.
    Buoninconti R; Motolese M; Rubegni M
    J Int Med Res; 1979; 7(6):519-23. PubMed ID: 391625
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A comparison of slow release with conventional oxprenolol: plasma concentrations and clinical effects.
    West MJ; Kendall MJ; Mitchard M; Faragher EB
    Br J Clin Pharmacol; 1976 Jun; 3(3):439-43. PubMed ID: 788749
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.